Jianfeng Group Pro 2015-017(10-14 Announcement of Rising Change)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group Announcement No.: 2015-017
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Abnormal Stock Trading Fluctuations
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Important Content Reminder:
Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company" or "the Company") shares on July 10, 13 and 14, 2015 The deviation of the daily closing price increase has exceeded 20% for three consecutive trading days, which is an abnormal fluctuation in stock trading.
Details of Abnormal Fluctuations in 1. Stock Trading
The company's stock has accumulated more than 20% of the daily closing price increase deviation for three consecutive trading days on July 10, 13, and 14, 2015 . According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", it is an abnormal fluctuation in stock trading.
2. the company's attention and verification of relevant information
1 , after the company's self-examination, the company's current production and operation activities are normal; There are no major issues that should be disclosed but not disclosed that affect abnormal stock price fluctuations.
2 . After consulting with the company's controlling shareholders and actual controllers, it is confirmed that the company, the company's controlling shareholders and actual controllers do not have major information that should be disclosed but not disclosed, including but not limited to the company's Major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, business restructuring, asset divestiture and asset injection.
Statement 3. whether there is material information that should be disclosed but not disclosed
The board of directors of the company confirmed that according to the Shanghai Stock Exchange Stock Listing Rules and other relevant regulations, the company does not have any disclosure. Undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matter, the board of directors has not been informed that the company has information that should be disclosed but not disclosed in accordance with the "Shanghai Stock Exchange Stock Listing Rules" and other relevant regulations, which has a greater impact on the trading prices of the company's stocks and derivatives.
Risk Tips deemed necessary by 4. listed companies
The company's designated information disclosure website is the Shanghai Stock Exchange website (www.sse.com.cn ), and the designated information disclosure newspapers are "Shanghai Securities News" and "China Securities News". All publicly disclosed information of the company is subject to the announcements published on the above designated websites and newspapers. Investors are invited to invest rationally, pay attention to investment risk.
is hereby announced.
Board of Directors of Zhejiang Jianfeng Group Co., Ltd.
July 14, 2015
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page